Stereotactic Radiation Therapy Market By Product Type (SRS Systems, SBRT Systems, Linear Accelerators, Robotic Systems); By Application (Oncology, Neurology); By End User (Hospitals, Oncology Centers, Research Institutions, Contract Research Organizations); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Stereotactic Radiation Therapy ( SRT ) Market is anticipated to grow significantly between 2024 and 2030, with an estimated market size of USD 1.4 billion in 2024, and a projected CAGR of 8.5%, reaching USD 2.9 billion by 2030, confirms Strategic Market Research.

 

SRT has emerged as a transformative technique in the treatment of various cancers and brain disorders, delivering high doses of radiation precisely to targeted tumors while minimizing damage to surrounding healthy tissue.

 

This market’s growth trajectory is largely driven by increasing incidences of cancer and neurological disorders, as well as significant technological advancements in imaging and radiation delivery systems. The rise in demand for non-invasive treatment options, coupled with improving healthcare infrastructure, is further pushing adoption rates.

 

Stereotactic radiation therapy is essential in treating tumors in areas where traditional surgery might be risky or unfeasible, such as in the brain, spine, and other sensitive regions. This makes SRT particularly crucial in the oncology and neurology sectors, where precision in treatment is paramount. The development of techniques like Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) , both subsets of SRT, is expanding its applicability and driving market expansion.

 

Key macro forces at play include:

• Technological Advancements : Innovations such as real-time imaging, robotic positioning systems, and improved radiation delivery techniques have made SRT more precise and effective, which is accelerating its uptake in clinical settings.

• Regulatory Approvals : Governments and regulatory bodies, such as the FDA and EMA , continue to approve newer devices and treatment protocols, paving the way for wider adoption.

• Increasing Cancer Burden : With the global increase in cancer cases, particularly in developing regions, the demand for precise, non-invasive cancer treatment options like SRT is growing rapidly.

• Growing Focus on Minimally Invasive Therapies : As patients increasingly demand treatments that offer shorter recovery times and reduced risks, SRT’s non-invasive nature is positioning it as a preferred choice for oncologists.

 

Key stakeholders driving the market include:

• Medical Device Manufacturers : Companies like Varian Medical Systems , Accuray , and Elekta are leading the charge with their cutting-edge radiation therapy systems.

• Healthcare Providers : Hospitals, specialized cancer treatment centers , and neurology clinics play a critical role in adopting and integrating SRT solutions.

• Government & Regulatory Bodies : These organizations are vital in ensuring the safety and efficacy of SRT technologies, promoting faster adoption through clear guidelines and support.

• Investors : With the growing emphasis on cancer and neurological disorder treatments, venture capitalists and private equity firms are increasingly focused on funding innovations in SRT technology.

The growing prevalence of cancer and neurological disorders, along with the adoption of advanced SRT systems, is likely to lead to widespread treatment access in the coming years. This represents a major growth opportunity for stakeholders within this ecosystem.

 

Market Segmentation And Forecast Scope

The Stereotactic Radiation Therapy (SRT) Market is segmented across various dimensions to offer a comprehensive view of its potential growth areas. These include product types , applications , end users , and regions . Let’s break down each segment in detail.

By Product Type

SRT systems can be categorized primarily into machines and software . The machine segment encompasses advanced linear accelerators (LINAC), robotic stereotactic systems, and other radiation delivery platforms used in SRT procedures. The software segment covers the diagnostic, planning, and treatment software tools that help optimize and personalize radiation treatment for patients.

• Linear Accelerators (LINACs) : This segment will remain the largest contributor to the market, accounting for approximately 62% of the overall market share in 2024. Their advanced features, such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), allow for highly targeted radiation doses with minimal exposure to healthy tissues.

• Robotic Stereotactic Systems : A faster-growing sub-segment within SRT, these systems are expected to see an increase in adoption due to their precision and efficiency, making them particularly suitable for difficult-to-reach tumors in the brain and spine.

 

By Application

SRT is employed in treating a wide range of medical conditions, but its primary applications lie in oncology and neurology .

• Oncology : The use of SRT in cancer treatment, particularly for brain, lung, prostate, and spinal tumors , remains dominant. With the global incidence of cancer rising, this segment is expected to account for approximately 75% of the market share in 2024. SRT is particularly effective for tumors that are small and well-defined, where traditional surgery may be too risky.

• Neurology : SRT is also gaining traction in the treatment of neurological disorders, including benign brain tumors , arteriovenous malformations (AVMs), and trigeminal neuralgia. This segment is growing rapidly, with expected growth driven by improved patient outcomes and the increasing adoption of non-invasive methods.

 

By End User

The primary end users of stereotactic radiation therapy systems are hospitals , oncology centers , and research institutions .

• Hospitals and Oncology Centers : These facilities account for the largest share of the market, driven by increasing patient volumes and the expansion of cancer care services. This segment is expected to maintain a dominant share, with hospitals making up about 55% of total market demand by 2024.

• Research Institutions : With advancements in clinical trials and the focus on developing more effective radiation techniques, research institutions are emerging as a key adopter. Their growing role in the development of new SRT technologies is vital to market evolution, especially in the neurology space.

 

By Region

The adoption of SRT varies significantly across different regions. The key markets include North America , Europe , Asia-Pacific , and LAMEA (Latin America, Middle East, and Africa).

• North America : North America is the largest regional market, driven by the high healthcare infrastructure and advanced oncology treatments in the U.S. and Canada. The region is expected to account for 40% of the global market in 2024, with steady growth projected through 2030.

• Europe : Europe follows closely, with a strong presence in Germany, France, and the U.K., where advancements in SRT technology are supported by rigorous clinical standards and government-backed healthcare systems. Europe is projected to grow at a CAGR of 7% from 2024 to 2030.

• Asia-Pacific : This region will witness the fastest growth due to increasing healthcare investments in countries like China, India, and Japan. The adoption of SRT in emerging economies is expected to rise sharply as healthcare systems expand and cancer treatment becomes more accessible. The CAGR for Asia-Pacific is expected to exceed 10% through 2030.

• LAMEA : Latin America, the Middle East, and Africa represent smaller yet growing markets. These regions face challenges such as limited healthcare budgets and infrastructure, but they offer strong opportunities due to the rising prevalence of cancer and neurological conditions.

Given the diversity in applications and technological advancements, the SRT market has broad opportunities for growth in various regions, especially in Asia-Pacific where adoption rates are still catching up.

 

Market Trends And Innovation Landscape

The Stereotactic Radiation Therapy (SRT) Market is experiencing continuous innovation, driven by both technological advancements and the evolving needs of healthcare providers. The combination of new techniques, integration with cutting-edge technologies, and an increasing focus on precision treatments is reshaping the SRT landscape. Several key trends and innovations are fueling growth in this sector.

Technological Innovations in Imaging and Delivery Systems

One of the primary drivers of growth in the SRT market is the ongoing improvement in imaging technologies that enhance the precision of radiation delivery. Advances in magnetic resonance imaging (MRI) , positron emission tomography (PET) , and computed tomography (CT) imaging enable real-time visualization of tumors , allowing clinicians to target them with higher accuracy.

• Image-Guided Radiation Therapy (IGRT) : This technique is becoming more integrated into SRT systems, offering enhanced targeting accuracy. With IGRT , radiation beams are adjusted in real-time based on the tumor's position and size, reducing the chances of errors and improving outcomes.

• Real-Time Tumor Tracking : A significant leap forward is the development of systems capable of tracking tumors in real-time, even as they move during respiration or due to body changes. This is especially crucial for lung and abdominal tumors , which are sensitive to movement. Systems like Calypso and CyberKnife are pioneering this capability.

 

Integration with Robotics and Automation

Automation and robotics are significantly enhancing the precision and efficiency of SRT systems. Robotic stereotactic systems , which can reposition patients and adjust the radiation beam in real-time, are reducing treatment times and improving patient comfort.

• CyberKnife and TrueBeam Systems : These systems, which combine robotic arms with linear accelerators, offer high levels of accuracy in delivering radiation beams, even to tumors located in challenging anatomical areas such as the brain or spine. Their ability to perform real-time adjustments based on continuous feedback is positioning them as leaders in the non-invasive treatment space.

 

Adoption of Artificial Intelligence (AI) in Treatment Planning

The role of Artificial Intelligence (AI) in SRT is rapidly growing, particularly in treatment planning and data analysis. AI is being integrated into SRT systems to help clinicians optimize radiation plans more effectively by analyzing large datasets of tumor characteristics and patient responses to previous treatments.

• AI-Powered Treatment Planning : AI algorithms are now capable of suggesting optimal radiation doses and treatment schedules based on the unique characteristics of each patient’s tumor . These AI tools can significantly reduce planning time and minimize human error, making them invaluable in clinical settings where time and precision are critical.

• Machine Learning for Predictive Analytics : With machine learning techniques, AI is beginning to predict patient outcomes based on historical data. This allows for personalized treatment plans that can be adjusted dynamically during the course of therapy, improving success rates and reducing side effects.

 

Precision and Personalized Treatments

There is a growing trend toward personalized medicine in cancer treatment, and SRT is well-positioned to benefit from this shift. The ability of SRT to precisely target tumors and minimize damage to surrounding healthy tissue makes it an ideal technique for individualized treatment regimens.

• Tumor Biology-Based Customization : Future advancements will likely involve the integration of genetic and molecular tumor profiling, which will allow for even more precise targeting of radiation. This will enable oncologists to tailor radiation therapy based on the biological behavior of individual tumors , improving treatment efficacy and reducing adverse effects.

• Adaptive Radiation Therapy (ART) : Another key innovation is the adoption of ART, which adjusts the radiation dose in response to changes in the tumor size or position during the course of treatment. This makes it possible to continually optimize treatment, increasing the likelihood of tumor eradication while minimizing side effects.

 

Mergers, Partnerships, and Collaborations

The SRT market is witnessing an increase in strategic partnerships and mergers aimed at expanding technological capabilities and improving treatment offerings. Notable examples include collaborations between medical device manufacturers and hospitals to co-develop new treatment protocols and enhance the accessibility of SRT systems.

• Partnerships with AI Companies : Several SRT system providers are partnering with AI startups to incorporate machine learning capabilities into their platforms, further improving the precision of treatment planning and delivery.

• Collaborations with Research Institutions : Medical device companies are also working closely with academic and research institutions to refine SRT techniques, especially in the context of neuro-oncology and complex tumor treatments.

The continuous innovation in both hardware and software for SRT is transforming the way radiation therapy is delivered, pushing the boundaries of what is possible in precision medicine. The future of SRT is increasingly tied to AI, robotics, and real-time adaptive technologies.

 

Competitive Intelligence And Benchmarking

The Stereotactic Radiation Therapy (SRT) Market is characterized by a competitive landscape featuring a mix of established players and innovative newcomers. Leading companies are heavily invested in developing and refining SRT technologies, focusing on improving accuracy, treatment planning, and patient outcomes. Here's a look at the main players in the market and their strategic approaches.

Varian Medical Systems

Varian Medical Systems, now part of Siemens Healthineers , remains a dominant force in the SRT market. The company offers a broad range of linear accelerators and radiation therapy systems , with a strong emphasis on precision treatment and patient-centric technologies.

• Strategy : Varian’s strategic focus is on providing high-end, integrated systems for oncology treatment. Their TrueBeam system, for example, is widely used for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). Varian also invests heavily in R&D and has recently increased its focus on AI-powered treatment planning .

• Global Reach : Varian holds a significant share of the global market, especially in North America and Europe . Its strong relationships with major healthcare providers ensure a broad presence across high-demand regions.

• Product Differentiation : Varian differentiates itself with its robust support services, extensive customer training programs, and its ability to integrate advanced imaging with radiation delivery systems.

 

Accuray Incorporated

Accuray is known for its innovative radiation therapy technologies, including the CyberKnife system and the Radixact treatment delivery platform. Accuray has carved out a niche in stereotactic radiosurgery and stereotactic body radiation therapy.

• Strategy : Accuray focuses on precision and non-invasive therapies, with a commitment to developing systems that combine radiation delivery with real-time tumor tracking. Their CyberKnife system, for example, is highly valued for treating brain and spinal tumors without the need for invasive surgery.

• Global Reach : Accuray has a strong presence in both North America and Asia-Pacific regions, especially in countries with highly advanced healthcare infrastructure.

• Product Differentiation : Accuray differentiates itself with its proprietary CyberKnife system, which is unique in its use of real-time tracking and robotic positioning to deliver radiation accurately, even to tumors that move during respiration.

 

Elekta AB

Elekta is another key player in the SRT market, offering advanced linear accelerators , Gamma Knife radiosurgery , and treatment planning systems . Elekta’s focus is on providing holistic solutions that include both the technology and the necessary software for precise radiation therapy.

• Strategy : Elekta’s strategy is centered around providing comprehensive treatment solutions that integrate advanced imaging with radiation delivery . Their Leksell Gamma Knife is widely used for the treatment of brain tumors, while the Versa HD linear accelerator targets other areas of the body with high precision.

• Global Reach : Elekta has a strong international presence, particularly in Europe, North America, and select Asia-Pacific countries.

• Product Differentiation : Elekta differentiates itself with its focus on delivering both targeted radiation and high-throughput solutions, offering a balance of speed and precision in treatment planning.

 

RaySearch Laboratories

RaySearch Laboratories is a leader in the development of radiation therapy treatment planning software . The company offers cutting-edge solutions to enhance precision and outcomes in stereotactic radiation therapy .

• Strategy : RaySearch is known for its RayStation treatment planning system, which is highly regarded for its ability to integrate imaging and radiation delivery into a unified system. The company’s strategy is focused on creating software solutions that enhance the clinical capabilities of existing SRT platforms.

• Global Reach : While smaller than the hardware manufacturers, RaySearch has a strong presence in Europe and North America , focusing heavily on partnerships with leading radiation therapy providers.

• Product Differentiation : RaySearch’s software provides a distinct advantage by integrating AI-based treatment planning and adaptive therapy protocols, making it easier for healthcare providers to customize treatment based on real-time data.

 

IBA Group

The IBA Group (Ion Beam Applications) is a prominent player in the proton therapy and SRT market. Their Proteus® ONE system is a unique offering for proton therapy, which is often combined with stereotactic techniques for precise tumor treatment.

• Strategy : IBA’s strategy involves expanding its portfolio to include both proton therapy and SRT systems, positioning itself as a provider of next-generation radiation treatments. The company is investing heavily in proton beam therapy (PBT) as the next frontier in precise tumor treatment.

• Global Reach : IBA has a presence in North America , Europe , and Asia-Pacific , where proton therapy systems are gaining popularity for specialized treatment centers .

• Product Differentiation : IBA is leading the charge in integrating proton therapy with SRT, offering a unique combination that improves treatment efficacy, especially for tumors located near critical organs.

 

Competitive Dynamics

• Technological Leadership : The main competitive differentiators in the SRT market are precision , imaging integration , and the ability to treat complex tumors . Companies that offer high-resolution imaging and innovative tracking systems (e.g., Accuray’s CyberKnife ) have a competitive edge, especially for non-invasive treatments.

• Price Sensitivity : While there is moderate price sensitivity in emerging markets, healthcare providers in developed regions prioritize the performance and precision of equipment over cost, making quality and innovation the primary purchasing factors.

• Partnerships and Collaborations : Increasing collaborations between equipment manufacturers and software developers (like RaySearch ) will continue to drive innovation, improving treatment outcomes and operational efficiencies in radiation therapy.

The competitive landscape in the SRT market is highly dynamic, with key players focusing on precision, real-time imaging, and innovative treatment modalities. Moving forward, companies that can integrate AI, robotics, and personalized treatment planning will have the strongest market positions.

 

Regional Landscape And Adoption Outlook

The Stereotactic Radiation Therapy (SRT) Market is witnessing varying rates of adoption and growth across different global regions. While developed regions like North America and Europe currently dominate the market, emerging markets in Asia-Pacific and Latin America are expected to see rapid growth in the coming years. Let's dive into the regional dynamics that are shaping the future of this market.

North America

North America is the largest and most mature market for stereotactic radiation therapy, primarily driven by robust healthcare infrastructure, high adoption rates of advanced medical technologies, and an increasing prevalence of cancer.

• Market Size and Growth : The North American market is expected to account for approximately 40% of the global SRT market in 2024, with steady growth continuing through 2030. The U.S. leads in both the adoption of cutting-edge technologies and the number of SRT systems installed.

• Regulatory Environment : Regulatory bodies, particularly the FDA , play a significant role in shaping the market. The stringent regulatory standards in North America ensure that only the most effective and safe SRT systems are approved, which supports the continued growth of high-performance systems like Varian's TrueBeam and Accuray's CyberKnife .

• Adoption Factors : Increasing cancer rates and a preference for non-invasive treatments are major factors driving SRT adoption. In addition, a large number of specialized cancer centers and hospitals are equipped with the latest SRT systems, helping to further promote market growth.

 

Europe

Europe follows closely behind North America in terms of market size, but with varying adoption rates across countries. Regions like Germany , France , and the U.K. have particularly strong markets for SRT due to their well-established healthcare systems and high standards of medical care.

• Market Size and Growth : Europe is expected to make up about 30% of the global market in 2024. The growth rate is expected to remain stable, with a CAGR of 7% over the forecast period.

• Regulatory and Healthcare Systems : The European Medicines Agency (EMA) plays a crucial role in ensuring that new technologies meet the high standards required for patient safety and efficacy. In addition, the region's commitment to sustainability and reducing the ecological footprint of medical procedures further boosts the adoption of systems that require fewer resources, such as Elekta's Versa HD .

• Adoption Factors : Europe has strong government support for cancer care initiatives, with growing investments in advanced radiation technologies. Additionally, the demand for green technologies in healthcare is increasingly influencing purchasing decisions, making SRT a popular choice in countries like Germany and the U.K. , which have implemented environmental policies that encourage energy-efficient medical devices.

 

Asia-Pacific

Asia-Pacific is poised to be the fastest-growing region for the SRT market, driven by an increasing cancer burden, expanding healthcare access, and growing investments in advanced medical technologies, particularly in China , India , and Japan .

• Market Size and Growth : This region is expected to post the highest CAGR , surpassing 10% between 2024 and 2030. Factors such as rapid urbanization, improving healthcare infrastructure, and the increasing incidence of cancer are contributing to the adoption of SRT.

• Regulatory and Healthcare Trends : While some countries in the region face regulatory hurdles, China and India are making strides to introduce more stringent regulations around cancer treatments, facilitating the introduction of innovative medical devices. The government’s growing focus on healthcare infrastructure improvements will further fuel the adoption of SRT systems.

• Adoption Factors : The shift toward precision medicine and minimally invasive treatments, especially in Japan and South Korea , is a major driving force. Moreover, the increasing number of cancer centers and radiation therapy facilities in India and China presents an opportunity for companies to establish a strong presence in these high-growth markets.

 

Latin America, Middle East, and Africa (LAMEA)

While LAMEA remains a smaller portion of the global SRT market, it represents an area with significant potential for future growth. Countries in Latin America like Brazil and Mexico , along with Saudi Arabia and South Africa in the Middle East and Africa , are making strides in improving their cancer care capabilities, driven by both public and private sector investments.

• Market Size and Growth : LAMEA is expected to remain a smaller part of the market, but with growing adoption, particularly in Brazil , Argentina , and Saudi Arabia , which are expected to grow at CAGR rates above 8% from 2024 to 2030.

• Regulatory and Healthcare Development : Regulatory frameworks in Latin America are gradually evolving, and several countries are improving their standards for cancer care. As a result, there is growing demand for advanced radiotherapy technologies.

• Adoption Factors : The need for cost-effective treatment options and the rising cancer burden in these regions are contributing to the gradual adoption of SRT systems. While healthcare infrastructure in some regions remains underdeveloped, countries like Brazil are seeing an increase in healthcare spending, which bodes well for the SRT market.

The regional disparities in SRT adoption highlight opportunities for market players to tailor their strategies to local conditions. While North America and Europe lead in market size and technological sophistication, Asia-Pacific and LAMEA are emerging as high-growth areas, creating new avenues for innovation and expansion.

 

End-User Dynamics And Use Case

The Stereotactic Radiation Therapy (SRT) Market serves a wide array of end users, each utilizing SRT technology to address specific needs within oncology and neurology. The adoption of SRT varies depending on the type of healthcare provider, patient demographics, and regional factors. Key end users include hospitals , oncology centers , research institutions , and contract research organizations (CROs) , each playing a crucial role in driving demand for advanced radiation therapy solutions.

Hospitals and Oncology Centers

Hospitals and oncology centers are the largest end-user groups for SRT systems. These healthcare providers are on the frontlines of cancer treatment and are increasingly adopting SRT due to its non-invasive nature, precision, and ability to treat tumors in difficult-to-reach areas.

• Use Case : In a major oncology hospital in the U.S. , doctors use Stereotactic Body Radiation Therapy (SBRT) to treat early-stage lung cancer patients. These patients have tumors that are not amenable to surgery, and SRT allows for a high dose of radiation to be delivered with minimal risk to surrounding healthy tissues. This non-invasive treatment option has been shown to improve survival rates, reduce recovery times, and increase patient satisfaction compared to traditional radiation treatments.

• Adoption Drivers : The increasing cancer burden, especially for tumors in sensitive areas like the brain, spine, and lungs, is pushing hospitals and oncology centers to adopt advanced SRT systems. The benefits of SRT, such as its precision and ability to minimize side effects, are critical factors driving adoption in these settings.

 

Research Institutions and Academia

Research institutions, including universities and clinical research centers , play an essential role in advancing SRT technologies and expanding their applications in clinical practice. These institutions are key adopters of SRT systems, particularly for clinical trials, proof-of-concept studies, and basic research in oncology and neurology.

• Use Case : A leading research university in Europe is conducting a clinical trial to assess the effectiveness of Stereotactic Radiosurgery (SRS) in treating benign brain tumors . The trial aims to compare the outcomes of SRS versus traditional surgery. By using SRT, researchers are able to treat tumors with high precision, minimizing damage to surrounding brain tissue and enhancing patient recovery times. The success of this study is expected to significantly influence treatment guidelines for brain tumors globally.

• Adoption Drivers : Research institutions are motivated by the ability of SRT to provide highly accurate treatment with fewer side effects, especially in high-risk patient populations. As more data becomes available on the effectiveness of SRT in various cancer types and neurological disorders, its adoption is expected to expand.

 

Contract Research Organizations (CROs)

CROs are third-party service providers that conduct research and clinical trials on behalf of pharmaceutical and biotech companies. As drug developers increasingly incorporate SRT into their trials, CROs are adopting advanced SRT systems to support regulatory submissions and improve treatment precision.

• Use Case : A contract research organization in Asia-Pacific is collaborating with a global pharmaceutical company to test a new gene therapy for brain cancer. The CRO uses Stereotactic Radiosurgery (SRS) to target specific tumor cells in the brain with high precision while minimizing the impact on healthy tissue. By utilizing SRS, the CRO is able to enhance the accuracy of the trial and ensure compliance with stringent regulatory standards set by agencies like the FDA and EMA .

• Adoption Drivers : CROs are increasingly adopting SRT because it enhances the precision of clinical trials, particularly in fields like oncology and neurology. The growing demand for highly accurate data in clinical trials and regulatory filings is a significant driver for the adoption of SRT technologies in this segment.

 

Forensic and Environmental Labs

While forensic and environmental labs represent a smaller segment of the SRT market, these institutions are also leveraging SRT for specialized applications. Forensic labs use SRT for the analysis of small, hard-to-reach samples, while environmental labs may use SRT systems for the analysis of trace contaminants or toxins.

• Use Case : In a forensic laboratory in the U.S., SRT technology is used to analyze and identify DNA fragments in cases where traditional methods fail. By using highly targeted radiation doses, forensic scientists are able to isolate specific genetic markers from challenging biological samples, improving the accuracy of their analyses.

• Adoption Drivers : Forensic and environmental labs are typically more focused on niche applications of SRT, such as DNA analysis or contaminant detection . The precision and non-invasive nature of SRT make it an ideal tool for applications that require minimal sample disruption and high accuracy.

The diverse range of end users in the SRT market underscores its versatility and growing importance in both clinical and research settings. Whether for cancer treatment in hospitals, clinical trials in research institutions, or regulatory compliance in CROs, SRT is proving to be an essential tool in modern medicine.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• FDA Approval of Advanced SRT Systems : In 2024, Varian Medical Systems received FDA approval for its latest TrueBeam STx system , which integrates advanced imaging technology with precision radiation delivery. This approval allows for broader deployment of high-precision stereotactic body radiation therapy (SBRT) in the treatment of tumors in the brain, spine, and lung.

• Partnership between Accuray and a Leading Cancer Center : Accuray entered into a strategic partnership in 2023 with a major cancer treatment center in Europe to enhance the use of its CyberKnife SRS system in the treatment of brain and prostate cancer. The collaboration focuses on improving treatment protocols and expanding access to advanced SRT technologies in underrepresented regions.

• Expansion of AI in Treatment Planning : Elekta launched an enhanced version of its Versa HD system in 2024, incorporating AI-powered treatment planning software. The new software utilizes machine learning to optimize radiation doses and personalize treatment plans for individual patients, marking a significant step toward precision medicine.

• Introduction of Robotic SRT Systems for Spine Tumors : In 2023, Accuray introduced a new robotic arm feature for its Radixact treatment system , allowing for improved treatment accuracy in patients with spine tumors . The robotic system’s ability to adjust patient positioning in real-time is a breakthrough in non-invasive treatment for tumors located near sensitive spinal regions.

Opportunities

• Emerging Markets (Asia-Pacific and LAMEA) : The growing adoption of advanced radiation technologies in Asia-Pacific and Latin America presents significant opportunities for market expansion. As healthcare infrastructure improves in countries like China , India , and Brazil , there is a rising demand for cutting-edge, non-invasive treatments like SRT. Companies that can navigate local regulations and provide cost-effective solutions will be poised for growth in these regions.

• Integration of AI and Robotics : The integration of AI and robotics into SRT systems offers exciting prospects for improving the precision, efficiency, and patient outcomes. AI-driven treatment planning , coupled with real-time tumor tracking and robotic repositioning , can significantly enhance treatment accuracy while reducing human error. This trend will drive demand for high-tech systems and attract investment from healthcare providers seeking to stay ahead in the competitive oncology space.

• Increasing Cancer Burden : The global rise in cancer cases, particularly in regions with aging populations, presents a consistent growth opportunity for the SRT market. As the demand for effective, non-invasive treatments continues to rise, SRT systems are becoming an essential part of cancer treatment protocols worldwide. This trend is particularly strong in developed markets where there is a greater focus on precision medicine.

• Non-Invasive Treatment for Neurological Disorders : Beyond oncology, there is growing interest in using SRT for treating neurological disorders , such as benign brain tumors , trigeminal neuralgia , and vascular malformations . With advancements in imaging and radiation delivery, SRT is poised to become a key treatment modality in neurology, expanding its application beyond oncology.

 

Restraints

• High Capital and Maintenance Costs : One of the primary challenges facing the SRT market is the high upfront capital cost of advanced radiation therapy systems. For many hospitals, especially in emerging markets, the initial investment required to acquire and maintain SRT systems can be prohibitively expensive. Additionally, ongoing maintenance and calibration costs can further strain healthcare budgets, limiting access to these technologies in resource-constrained regions.

• Lack of Trained Professionals : The successful implementation of SRT systems relies heavily on highly skilled professionals, including radiation oncologists , medical physicists , and radiologic technologists . The lack of sufficient trained personnel, especially in emerging markets, remains a significant barrier to the widespread adoption of SRT technologies. This skills gap can lead to suboptimal usage of systems and potentially lower treatment outcomes.

• Regulatory Challenges in Emerging Markets : Regulatory hurdles in emerging markets, including Asia-Pacific and LAMEA , can slow the adoption of SRT technologies. These regions often have complex approval processes, inconsistent regulatory standards, and challenges related to reimbursement policies, which can delay market entry for new technologies and affect the pace of adoption.

• Patient Access and Insurance Limitations : Despite the growing demand for SRT, patient access to these treatments can be limited by factors such as insurance coverage and geographic accessibility . In some regions, insurance companies may not cover the cost of advanced SRT systems, and patients may need to travel long distances to access treatment, further reducing accessibility.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.4 Billion
Revenue Forecast in 2030	USD 2.9 Billion
Overall Growth Rate	CAGR of 8.5% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	SRS Systems, SBRT Systems, Linear Accelerators, Robotic Systems
By Application	Oncology, Neurology
By End User	Hospitals, Oncology Centers, Research Institutions, CROs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., U.K., Germany, China, India, Japan, Brazil, etc.
Market Drivers	Increasing cancer burden, Technological advancements, Growth in non-invasive treatment demand
Customization Option	Available upon request